

Table S1 Cardiovascular toxicity definitions as established by the 2022 ESC guidelines on cardio-oncology

CTR-CVT	Severity	Definitions
Symptomatic CTR-CVT	Very severe	HF requiring inotropic support, mechanical circulatory support, or consideration of transplantation
	Severe	HF hospitalization
	Moderate	Need for outpatient intensification of diuretic and HF therapy
	Mild	Mild HF symptoms, no intensification of therapy required
Asymptomatic CTR-CVT	Severe	New LVEF reduction to < 40%
		New LVEF reduction by ≥ 10 percentage points to an LVEF of 40%~49% OR
	Moderate	New LVEF reduction by <10 percentage points to an LVEF of 40%~49% and either new relative decline in GLS by >15% from baseline or new rise in cardiac biomarkers
	Mild	LVEF $\geq 50\%$ and new relative decline in GLS by >15% from baseline and/or new rise in cardiac biomarkers

Abbreviations: CTR-CVT, cancer therapy-related cardiovascular toxicity; HF, heart failure; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction.

Table S2 Evidence-based cardioprotective medications for the cancer therapy-related cardiovascular toxicity

Category	Agent	Chemotherapy	Evidence
ACEI	Enalapril	Anthracyclines	OVERCOME (Bosch et al.) (1) ICOS-ONE (Cardinale et al.) (2)
ACEI	Lisinopril	Trastuzumab; stratified by anthracycline use	Kentucky (Guglin et al.) (3)
ACEI	Perindopril	Trastuzumab	MANTICORE (Pituskin et al.) (4)
ARB	Candesartan	Anthracyclines+trastuzumab	PRADA (Gulati et al.) (5) PRADA substudy (Gulati et al.) (6) PRADA extended follow-up (Heck et al.) (7)
ARB	Candesartan	Trastuzumab	Boekhout et al. (8)
BB	Metoprolol succinate	Anthracyclines+trastuzumab	PRADA (Gulati et al.) (5) PRADA substudy (Gulati et al.) (6) PRADA extended follow-up (Heck et al.) (7)
BB	Bisoprolol	Trastuzumab	MANTICORE (Pituskin et al.) (4)
CCB	Carvedilol	Anthracyclines	OVERCOME (Bosch et al.) (1) CECCY (Avila et al.) (9)
CCB	Carvedilol	Trastuzumab; stratified by anthracycline use	Kentucky (Guglin et al.) (3)
MRA	Spironolactone	Anthracyclines	Akpek et al. (10)
Statins	Atorvastatin	Anthracyclines	Acar et al. (11)

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BB, beta-blockers; CCB, calcium channel blockers; CECCY, Carvedilol Effect in Preventing Chemotherapy-Induced Cardiotoxicity; ICOS-ONE, International Cardio-Oncology Society-ONE; MANTICORE, Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research; MRA, mineralocorticoid receptor antagonists; OVERCOME, preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies; PRADA, Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy.

Table S3 Meta-analyses of primary prevention of cancer therapy-related cardiovascular toxicity

Category/Agent	Chemotherapy	Meta-analysis
ACEI	Anthracyclines, trastuzumab, cyclophosphamide, taxanes, platinum agents, 5-FU, and others	Li et al. (12)
ACEI/ARB	Anthracyclines	Vaduganathan et al. (13) Caspani et al. (14)
ACEI/ARB	Anthracyclines+trastuzumab	Fang et al. (15)
BB	Anthracyclines	Vaduganathan et al. (13) Huang et al. (16) Caspani et al. (14)
BB	Anthracyclines, trastuzumab, cyclophosphamide, taxanes, platinum agents, 5-FU, and others	Li et al. (12)
MRA	Anthracyclines	Vaduganathan et al. (13) Caspani et al. (14)
Dexrazoxane	Anthracyclines	Macedo et al. (17)
Statins	Anthracyclines, trastuzumab, cyclophosphamide, taxanes, platinum agents, 5-FU, and others	Li et al. (12)

Abbreviations: 5-FU, 5-fluorouracil; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BB, beta-blockers; MRA, mineralocorticoid receptor antagonists; RAASi, renin-angiotensin aldosterone system inhibitors.

References

1. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). *J Am Coll Cardiol*. 2013;61(23):2355-62.
2. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. *Eur J Cancer*. 2018;94:126-37.
3. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. *J Am Coll Cardiol*. 2019;73(22):2859-68.
4. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. *J Clin Oncol*. 2017;35(8):870-7.
5. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Eur Heart J*. 2016;37(21):1671-80.
6. Gulati G, Heck SL, Rosjo H, Ree AH, Hoffmann P, Hagve TA, et al. Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (prevention of cardiac dysfunction during adjuvant breast cancer therapy) study. *J Am Heart Assoc*. 2017;6(11).
7. Heck SL, Mecinaj A, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Circulation*. 2021;143(25):2431-40.
8. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. *JAMA Oncol*. 2016;2(8):1030-7.
9. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr., das Dores Cruz F, Goncalves Brandao SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. *J Am Coll Cardiol*. 2018;71(20):2281-90.
10. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. *Eur J Heart Fail*. 2015;17(1):81-9.
11. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. *J Am Coll Cardiol*. 2011;58(9):988-9.
12. Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B, et al. Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials. *Pharmacol Res*. 2020;151:104577.
13. Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. *JACC CardioOncol*. 2019;1(1):54-65.
14. Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis. *Intern Emerg Med*. 2021;16(2):477-86.
15. Fang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials. *Heart Fail Rev*. 2021;26(1):101-9.
16. Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, et al. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. *Heart Fail Rev*. 2019;24(3):325-33.
17. Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. *JACC CardioOncol*. 2019;1(1):68-79.